- Home
- CGO vs LUNG Comparison
CGO vs LUNG Comparison
Compare CGO & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGO
- LUNG
- Stock Information
- Founded
- CGO 2004
- LUNG 1995
- Country
- CGO United States
- LUNG United States
- Employees
- CGO N/A
- LUNG N/A
- Industry
- CGO Investment Managers
- LUNG Industrial Specialties
- Sector
- CGO Finance
- LUNG Health Care
- Exchange
- CGO Nasdaq
- LUNG Nasdaq
- Market Cap
- CGO 111.0M
- LUNG 124.0M
- IPO Year
- CGO N/A
- LUNG 2020
- Fundamental
- Price
- CGO $11.63
- LUNG $2.58
- Analyst Decision
- CGO
- LUNG Buy
- Analyst Count
- CGO 0
- LUNG 6
- Target Price
- CGO N/A
- LUNG $11.53
- AVG Volume (30 Days)
- CGO 34.7K
- LUNG 360.8K
- Earning Date
- CGO 01-01-0001
- LUNG 07-30-2025
- Dividend Yield
- CGO 9.25%
- LUNG N/A
- EPS Growth
- CGO N/A
- LUNG N/A
- EPS
- CGO N/A
- LUNG N/A
- Revenue
- CGO N/A
- LUNG $87,473,000.00
- Revenue This Year
- CGO N/A
- LUNG $18.02
- Revenue Next Year
- CGO N/A
- LUNG $18.17
- P/E Ratio
- CGO N/A
- LUNG N/A
- Revenue Growth
- CGO N/A
- LUNG 19.84
- 52 Week Low
- CGO $7.90
- LUNG $2.50
- 52 Week High
- CGO $10.93
- LUNG $9.37
- Technical
- Relative Strength Index (RSI)
- CGO 65.54
- LUNG 35.17
- Support Level
- CGO $11.30
- LUNG $2.50
- Resistance Level
- CGO $11.45
- LUNG $2.80
- Average True Range (ATR)
- CGO 0.12
- LUNG 0.18
- MACD
- CGO -0.00
- LUNG 0.01
- Stochastic Oscillator
- CGO 92.68
- LUNG 13.82
About CGO Calamos Global Total Return Fund
Calamos Global Total Return Fund is a closed-end management investment company. The fund's investment objective is to provide total return through a combination of capital appreciation and current income. The fund invests in equities, convertible securities, and high-yield corporate bonds.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.